Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay

BACKGROUND: Currently there are no effective treatments for many neurodegenerative diseases. Reliable biomarkers for identifying and stratifying these diseases will be important in the development of future novel therapies. Lewy Body Dementia (LBD) is considered an under diagnosed form of dementia f...

Descripción completa

Detalles Bibliográficos
Autores principales: Heywood, Wendy E., Galimberti, Daniela, Bliss, Emily, Sirka, Ernestas, Paterson, Ross W., Magdalinou, Nadia K., Carecchio, Miryam, Reid, Emma, Heslegrave, Amanda, Fenoglio, Chiara, Scarpini, Elio, Schott, Jonathan M., Fox, Nick C., Hardy, John, Bahtia, Kailash, Heales, Simon, Sebire, Neil J., Zetterburg, Henrik, Mills, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666172/
https://www.ncbi.nlm.nih.gov/pubmed/26627638
http://dx.doi.org/10.1186/s13024-015-0059-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666172/
https://www.ncbi.nlm.nih.gov/pubmed/26627638
http://dx.doi.org/10.1186/s13024-015-0059-y

Ejemplares similares